TP53
Summary: This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons from identical transcript variants (PMIDs: 12032546, 20937277). [provided by RefSeq, Dec 2016].
Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
---|---|---|---|---|---|
tumor protein p53 | MIM:191170 | Ensembl:ENSG00000141510 | HGNC:HGNC:11998 | PA36679 | 17p13.1 |
GO terms in TP53
Term Type | Evidence Type | GO Term ID | GO Des. |
---|---|---|---|
BP | ISS | GO:0000122 | negative regulation of transcription by RNA polymerase II |
BP | IDA | GO:0000733 | DNA strand renaturation |
BP | TAS | GO:0006284 | base-excision repair |
BP | IMP | GO:0006289 | nucleotide-excision repair |
BP | IDA | GO:0006355 | regulation of transcription, DNA-templated |
BP | IMP | GO:0006355 | regulation of transcription, DNA-templated |
BP | IMP | GO:0006914 | autophagy |
BP | IDA | GO:0006974 | cellular response to DNA damage stimulus |
BP | IMP | GO:0006974 | cellular response to DNA damage stimulus |
BP | IMP | GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest |
BP | TAS | GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest |
BP | IDA | GO:0006978 | DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator |
BP | IMP | GO:0006978 | DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator |
BP | IDA | GO:0006983 | ER overload response |
BP | IDA | GO:0007050 | cell cycle arrest |
BP | IMP | GO:0007050 | cell cycle arrest |
BP | IEP | GO:0007265 | Ras protein signal transduction |
BP | IMP | GO:0007275 | multicellular organism development |
BP | IMP | GO:0007569 | cell aging |
BP | IDA | GO:0008104 | protein localization |
BP | TAS | GO:0008283 | cell proliferation |
BP | IDA | GO:0008285 | negative regulation of cell proliferation |
BP | IMP | GO:0008285 | negative regulation of cell proliferation |
BP | ISS | GO:0008285 | negative regulation of cell proliferation |
BP | ISS | GO:0008340 | determination of adult lifespan |
BP | IMP | GO:0009299 | mRNA transcription |
BP | IMP | GO:0010332 | response to gamma radiation |
BP | IDA | GO:0010628 | positive regulation of gene expression |
BP | IMP | GO:0010628 | positive regulation of gene expression |
BP | ISS | GO:0010628 | positive regulation of gene expression |
BP | IMP | GO:0016032 | viral process |
BP | TAS | GO:0016579 | protein deubiquitination |
BP | TAS | GO:0019221 | cytokine-mediated signaling pathway |
BP | TAS | GO:0030154 | cell differentiation |
BP | IMP | GO:0030308 | negative regulation of cell growth |
BP | IDA | GO:0030330 | DNA damage response, signal transduction by p53 class mediator |
BP | IMP | GO:0030330 | DNA damage response, signal transduction by p53 class mediator |
BP | IDA | GO:0031497 | chromatin assembly |
BP | IMP | GO:0031571 | mitotic G1 DNA damage checkpoint |
BP | IDA | GO:0032461 | positive regulation of protein oligomerization |
BP | IDA | GO:0034644 | cellular response to UV |
BP | IEP | GO:0035690 | cellular response to drug |
BP | IDA | GO:0042149 | cellular response to glucose starvation |
BP | IDA | GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
BP | IMP | GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
BP | IDA | GO:0042981 | regulation of apoptotic process |
BP | TAS | GO:0042981 | regulation of apoptotic process |
BP | IDA | GO:0043065 | positive regulation of apoptotic process |
BP | IMP | GO:0043066 | negative regulation of apoptotic process |
BP | ISS | GO:0043153 | entrainment of circadian clock by photoperiod |
BP | IDA | GO:0045892 | negative regulation of transcription, DNA-templated |
BP | IMP | GO:0045892 | negative regulation of transcription, DNA-templated |
BP | ISS | GO:0045892 | negative regulation of transcription, DNA-templated |
BP | IDA | GO:0045893 | positive regulation of transcription, DNA-templated |
BP | IMP | GO:0045893 | positive regulation of transcription, DNA-templated |
BP | IDA | GO:0045899 | positive regulation of RNA polymerase II transcriptional preinitiation complex assembly |
BP | IDA | GO:0045944 | positive regulation of transcription by RNA polymerase II |
BP | IGI | GO:0045944 | positive regulation of transcription by RNA polymerase II |
BP | IMP | GO:0045944 | positive regulation of transcription by RNA polymerase II |
BP | IEP | GO:0046677 | response to antibiotic |
BP | TAS | GO:0046827 | positive regulation of protein export from nucleus |
BP | TAS | GO:0046902 | regulation of mitochondrial membrane permeability |
BP | IMP | GO:0048147 | negative regulation of fibroblast proliferation |
BP | ISS | GO:0048512 | circadian behavior |
BP | ISS | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation |
BP | TAS | GO:0051097 | negative regulation of helicase activity |
BP | IEA | GO:0051123 | RNA polymerase II transcriptional preinitiation complex assembly |
BP | TAS | GO:0051262 | protein tetramerization |
BP | IMP | GO:0051289 | protein homotetramerization |
BP | IDA | GO:0051974 | negative regulation of telomerase activity |
BP | IDA | GO:0065003 | protein-containing complex assembly |
BP | ISS | GO:0070245 | positive regulation of thymocyte apoptotic process |
BP | IDA | GO:0071158 | positive regulation of cell cycle arrest |
BP | IMP | GO:0071158 | positive regulation of cell cycle arrest |
BP | IEP | GO:0071456 | cellular response to hypoxia |
BP | IMP | GO:0071479 | cellular response to ionizing radiation |
BP | IDA | GO:0071480 | cellular response to gamma radiation |
BP | IDA | GO:0072331 | signal transduction by p53 class mediator |
BP | IMP | GO:0072332 | intrinsic apoptotic signaling pathway by p53 class mediator |
BP | IDA | GO:0072717 | cellular response to actinomycin D |
BP | IDA | GO:0090200 | positive regulation of release of cytochrome c from mitochondria |
BP | IMP | GO:0090399 | replicative senescence |
BP | IMP | GO:0090403 | oxidative stress-induced premature senescence |
BP | TAS | GO:0097193 | intrinsic apoptotic signaling pathway |
BP | IDA | GO:0097252 | oligodendrocyte apoptotic process |
BP | IMP | GO:1900119 | positive regulation of execution phase of apoptosis |
BP | TAS | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
BP | TAS | GO:1901796 | regulation of signal transduction by p53 class mediator |
BP | TAS | GO:1902749 | regulation of cell cycle G2/M phase transition |
BP | IDA | GO:1902895 | positive regulation of pri-miRNA transcription by RNA polymerase II |
BP | ISS | GO:1990440 | positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress |
BP | IMP | GO:2000379 | positive regulation of reactive oxygen species metabolic process |
BP | IMP | GO:2001244 | positive regulation of intrinsic apoptotic signaling pathway |
CC | IDA | GO:0000790 | nuclear chromatin |
CC | IDA | GO:0005622 | intracellular |
CC | IDA | GO:0005634 | nucleus |
CC | IMP | GO:0005634 | nucleus |
CC | IDA | GO:0005654 | nucleoplasm |
CC | TAS | GO:0005654 | nucleoplasm |
CC | IDA | GO:0005669 | transcription factor TFIID complex |
CC | IDA | GO:0005730 | nucleolus |
CC | IDA | GO:0005737 | cytoplasm |
CC | IMP | GO:0005737 | cytoplasm |
CC | IDA | GO:0005739 | mitochondrion |
CC | IEA | GO:0005759 | mitochondrial matrix |
CC | IEA | GO:0005783 | endoplasmic reticulum |
CC | IDA | GO:0005829 | cytosol |
CC | TAS | GO:0005829 | cytosol |
CC | IDA | GO:0016363 | nuclear matrix |
CC | IDA | GO:0016604 | nuclear body |
CC | IDA | GO:0016605 | PML body |
CC | IDA | GO:0032991 | protein-containing complex |
CC | IMP | GO:0032991 | protein-containing complex |
MF | IDA | GO:0000978 | RNA polymerase II proximal promoter sequence-specific DNA binding |
MF | ISS | GO:0000980 | RNA polymerase II distal enhancer sequence-specific DNA binding |
MF | IDA | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
MF | ISA | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
MF | ISM | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
MF | NAS | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
MF | IDA | GO:0000990 | transcription factor activity, core RNA polymerase binding |
MF | IDA | GO:0001046 | core promoter sequence-specific DNA binding |
MF | IDA | GO:0001074 | transcription factor activity, RNA polymerase II proximal promoter sequence-specific DNA binding involved in preinitiation complex assembly |
MF | IPI | GO:0001085 | RNA polymerase II transcription factor binding |
MF | IPI | GO:0001094 | TFIID-class transcription factor binding |
MF | IDA | GO:0001228 | transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding |
MF | IPI | GO:0002020 | protease binding |
MF | IPI | GO:0002039 | p53 binding |
MF | IDA | GO:0003677 | DNA binding |
MF | IMP | GO:0003677 | DNA binding |
MF | IDA | GO:0003682 | chromatin binding |
MF | IDA | GO:0003700 | DNA-binding transcription factor activity |
MF | IMP | GO:0003700 | DNA-binding transcription factor activity |
MF | IDA | GO:0003730 | mRNA 3'-UTR binding |
MF | IDA | GO:0005507 | copper ion binding |
MF | IPI | GO:0005515 | protein binding |
MF | IDA | GO:0005524 | ATP binding |
MF | IPI | GO:0008134 | transcription factor binding |
MF | TAS | GO:0008270 | zinc ion binding |
MF | IPI | GO:0019899 | enzyme binding |
MF | IPI | GO:0019901 | protein kinase binding |
MF | IPI | GO:0019903 | protein phosphatase binding |
MF | IPI | GO:0030971 | receptor tyrosine kinase binding |
MF | IPI | GO:0031625 | ubiquitin protein ligase binding |
MF | IPI | GO:0035035 | histone acetyltransferase binding |
MF | IMP | GO:0042802 | identical protein binding |
MF | IPI | GO:0042802 | identical protein binding |
MF | IPI | GO:0042826 | histone deacetylase binding |
MF | IPI | GO:0043621 | protein self-association |
MF | IDA | GO:0044212 | transcription regulatory region DNA binding |
MF | IPI | GO:0046982 | protein heterodimerization activity |
MF | IPI | GO:0047485 | protein N-terminus binding |
MF | IPI | GO:0051087 | chaperone binding |
MF | IPI | GO:0051721 | protein phosphatase 2A binding |
MF | IPI | GO:0097718 | disordered domain specific binding |
MF | IDA | GO:1990841 | promoter-specific chromatin binding |
Gene expression in normal tissue: TP53
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in TP53
Database | Pathway ID | Pathway Des. |
---|---|---|
pharmgkb | PA165291507 | Fluoropyrimidine Pathway, Pharmacodynamics |
pharmgkb | PA165292163 | Doxorubicin Pathway (Cancer Cell), Pharmacodynamics |
pid | ap1_pathway | AP-1 transcription factor network |
pid | aurora_a_pathway | Aurora A signaling |
pid | bard1pathway | BARD1 signaling events |
pid | hdac_classiii_pathway | Signaling events mediated by HDAC Class III |
pid | hif1apathway | Hypoxic and oxygen homeostasis regulation of HIF-1-alpha |
pid | lkb1_pathway | LKB1 signaling events |
pid | myc_activpathway | Validated targets of C-MYC transcriptional activation |
pid | p38alphabetadownstreampathway | Signaling mediated by p38-alpha and p38-beta |
pid | p53downstreampathway | Direct p53 effectors |
pid | p53regulationpathway | p53 pathway |
pid | p75ntrpathway | p75(NTR)-mediated signaling |
pid | plk3_pathway | PLK3 signaling events |
pid | reg_gr_pathway | Glucocorticoid receptor regulatory network |
wikipathways | WP1403 | AMP-activated Protein Kinase (AMPK) Signaling |
wikipathways | WP1530 | miRNA Regulation of DNA Damage Response |
wikipathways | WP1545 | miRNAs involved in DNA damage response |
wikipathways | WP1601 | Fluoropyrimidine Activity |
wikipathways | WP1742 | TP53 Network |
wikipathways | WP176 | Folate Metabolism |
wikipathways | WP1772 | Apoptosis Modulation and Signaling |
wikipathways | WP179 | Cell Cycle |
wikipathways | WP2059 | Alzheimers Disease |
wikipathways | WP2249 | Metastatic brain tumor |
wikipathways | WP2261 | Signaling Pathways in Glioblastoma |
wikipathways | WP2363 | Gastric Cancer Network 2 |
wikipathways | WP2374 | Oncostatin M Signaling Pathway |
wikipathways | WP2431 | Spinal Cord Injury |
wikipathways | WP2446 | Retinoblastoma (RB) in Cancer |
wikipathways | WP2447 | Amyotrophic lateral sclerosis (ALS) |
wikipathways | WP2516 | ATM Signaling Pathway |
wikipathways | WP254 | Apoptosis |
wikipathways | WP2815 | Mammary gland development pathway - Involution (Stage 4 of 4) |
wikipathways | WP2828 | Bladder Cancer |
wikipathways | WP3286 | Copper homeostasis |
wikipathways | WP3303 | Rac1-Pak1-p38-MMP-2 pathway |
wikipathways | WP3611 | Photodynamic therapy-induced AP-1 survival signaling. |
wikipathways | WP3614 | Photodynamic therapy-induced HIF-1 survival signaling |
wikipathways | WP3639 | Apoptotic Signaling Pathway |
wikipathways | WP3646 | Hepatitis C and Hepatocellular Carcinoma |
wikipathways | WP3651 | Pathways Affected in Adenoid Cystic Carcinoma |
wikipathways | WP366 | TGF-beta Signaling Pathway |
wikipathways | WP3672 | LncRNA-mediated mechanisms of therapeutic resistance |
wikipathways | WP3807 | Regulation of TP53 Expression and Degradation |
wikipathways | WP382 | MAPK Signaling Pathway |
wikipathways | WP3981 | miRNA regulation of prostate cancer signaling pathways |
wikipathways | WP3982 | miRNA regulation of p53 pathway in prostate cancer |
wikipathways | WP399 | Wnt Signaling Pathway and Pluripotency |
wikipathways | WP4066 | Interleukin-4 and 13 signaling |
wikipathways | WP4155 | Endometrial cancer |
wikipathways | WP4172 | PI3K-Akt Signaling Pathway |
wikipathways | WP4191 | Caloric restriction and aging |
wikipathways | WP4206 | Hereditary Leiomyomatosis and Renal Cell Carcinoma Pathway |
wikipathways | WP4216 | Chromosomal and microsatellite instability in colorectal cancer |
wikipathways | WP4239 | EMT transition in Colorectal Cancer |
wikipathways | WP45 | G1 to S cell cycle control |
wikipathways | WP615 | Senescence and Autophagy in Cancer |
wikipathways | WP673 | ErbB Signaling Pathway |
wikipathways | WP707 | DNA Damage Response |
wikipathways | WP710 | DNA Damage Response (only ATM dependent) |
smpdb | SMP00436 | Vinblastine Action Pathway |
smpdb | SMP00437 | Vincristine Action Pathway |
smpdb | SMP00438 | Vindesine Action Pathway |
smpdb | SMP00439 | Vinorelbine Action Pathway |
netpath | Pathway_EGFR1 | EGFR1 |
netpath | Pathway_Oncostatin_M | Oncostatin_M |
netpath | Pathway_TGF_beta_Receptor | TGF_beta_Receptor |
kegg | hsa04010 | MAPK signaling pathway - Homo sapiens (human) |
kegg | hsa04071 | Sphingolipid signaling pathway - Homo sapiens (human) |
kegg | hsa04110 | Cell cycle - Homo sapiens (human) |
kegg | hsa04115 | p53 signaling pathway - Homo sapiens (human) |
kegg | hsa04137 | Mitophagy - animal - Homo sapiens (human) |
kegg | hsa04151 | PI3K-Akt signaling pathway - Homo sapiens (human) |
kegg | hsa04210 | Apoptosis - Homo sapiens (human) |
kegg | hsa04211 | Longevity regulating pathway - Homo sapiens (human) |
kegg | hsa04216 | Ferroptosis - Homo sapiens (human) |
kegg | hsa04218 | Cellular senescence - Homo sapiens (human) |
kegg | hsa04310 | Wnt signaling pathway - Homo sapiens (human) |
kegg | hsa04722 | Neurotrophin signaling pathway - Homo sapiens (human) |
kegg | hsa04919 | Thyroid hormone signaling pathway - Homo sapiens (human) |
kegg | hsa05014 | Amyotrophic lateral sclerosis (ALS) - Homo sapiens (human) |
kegg | hsa05016 | Huntington,s disease - Homo sapiens (human) |
kegg | hsa05160 | Hepatitis C - Homo sapiens (human) |
kegg | hsa05161 | Hepatitis B - Homo sapiens (human) |
kegg | hsa05162 | Measles - Homo sapiens (human) |
kegg | hsa05165 | Human papillomavirus infection - Homo sapiens (human) |
kegg | hsa05166 | HTLV-I infection - Homo sapiens (human) |
kegg | hsa05167 | Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human) |
kegg | hsa05168 | Herpes simplex infection - Homo sapiens (human) |
kegg | hsa05169 | Epstein-Barr virus infection - Homo sapiens (human) |
kegg | hsa05200 | Pathways in cancer - Homo sapiens (human) |
kegg | hsa05202 | Transcriptional misregulation in cancer - Homo sapiens (human) |
kegg | hsa05203 | Viral carcinogenesis - Homo sapiens (human) |
kegg | hsa05205 | Proteoglycans in cancer - Homo sapiens (human) |
kegg | hsa05206 | MicroRNAs in cancer - Homo sapiens (human) |
kegg | hsa05210 | Colorectal cancer - Homo sapiens (human) |
kegg | hsa05212 | Pancreatic cancer - Homo sapiens (human) |
kegg | hsa05213 | Endometrial cancer - Homo sapiens (human) |
kegg | hsa05214 | Glioma - Homo sapiens (human) |
kegg | hsa05215 | Prostate cancer - Homo sapiens (human) |
kegg | hsa05216 | Thyroid cancer - Homo sapiens (human) |
kegg | hsa05217 | Basal cell carcinoma - Homo sapiens (human) |
kegg | hsa05218 | Melanoma - Homo sapiens (human) |
kegg | hsa05219 | Bladder cancer - Homo sapiens (human) |
kegg | hsa05220 | Chronic myeloid leukemia - Homo sapiens (human) |
kegg | hsa05222 | Small cell lung cancer - Homo sapiens (human) |
kegg | hsa05223 | Non-small cell lung cancer - Homo sapiens (human) |
kegg | hsa05224 | Breast cancer - Homo sapiens (human) |
kegg | hsa05225 | Hepatocellular carcinoma - Homo sapiens (human) |
kegg | hsa05226 | Gastric cancer - Homo sapiens (human) |
kegg | hsa05230 | Central carbon metabolism in cancer - Homo sapiens (human) |
kegg | hsa05418 | Fluid shear stress and atherosclerosis - Homo sapiens (human) |
reactome | R-HSA-109581 | Apoptosis |
reactome | R-HSA-109582 | Hemostasis |
reactome | R-HSA-109606 | Intrinsic Pathway for Apoptosis |
reactome | R-HSA-111448 | Activation of NOXA and translocation to mitochondria |
reactome | R-HSA-114452 | Activation of BH3-only proteins |
reactome | R-HSA-1257604 | PIP3 activates AKT signaling |
reactome | R-HSA-1257604 | PIP3 activates AKT signaling |
reactome | R-HSA-1280215 | Cytokine Signaling in Immune system |
reactome | R-HSA-139915 | Activation of PUMA and translocation to mitochondria |
reactome | R-HSA-157118 | Signaling by NOTCH |
reactome | R-HSA-162582 | Signal Transduction |
reactome | R-HSA-162582 | Signal Transduction |
reactome | R-HSA-1640170 | Cell Cycle |
reactome | R-HSA-168256 | Immune System |
reactome | R-HSA-1912408 | Pre-NOTCH Transcription and Translation |
reactome | R-HSA-1912422 | Pre-NOTCH Expression and Processing |
reactome | R-HSA-212436 | Generic Transcription Pathway |
reactome | R-HSA-2262752 | Cellular responses to stress |
reactome | R-HSA-2559580 | Oxidative Stress Induced Senescence |
reactome | R-HSA-2559583 | Cellular Senescence |
reactome | R-HSA-2559584 | Formation of Senescence-Associated Heterochromatin Foci (SAHF) |
reactome | R-HSA-2559585 | Oncogene Induced Senescence |
reactome | R-HSA-2559586 | DNA Damage/Telomere Stress Induced Senescence |
reactome | R-HSA-2990846 | SUMOylation |
reactome | R-HSA-3108232 | SUMO E3 ligases SUMOylate target proteins |
reactome | R-HSA-3232118 | SUMOylation of transcription factors |
reactome | R-HSA-349425 | Autodegradation of the E3 ubiquitin ligase COP1 |
reactome | R-HSA-3700989 | Transcriptional Regulation by TP53 |
reactome | R-HSA-390466 | Chaperonin-mediated protein folding |
reactome | R-HSA-390471 | Association of TriC/CCT with target proteins during biosynthesis |
reactome | R-HSA-391251 | Protein folding |
reactome | R-HSA-392499 | Metabolism of proteins |
reactome | R-HSA-392499 | Metabolism of proteins |
reactome | R-HSA-449147 | Signaling by Interleukins |
reactome | R-HSA-453274 | Mitotic G2-G2/M phases |
reactome | R-HSA-5357801 | Programmed Cell Death |
reactome | R-HSA-5628897 | TP53 Regulates Metabolic Genes |
reactome | R-HSA-5633007 | Regulation of TP53 Activity |
reactome | R-HSA-5633008 | TP53 Regulates Transcription of Cell Death Genes |
reactome | R-HSA-5688426 | Deubiquitination |
reactome | R-HSA-5689880 | Ub-specific processing proteases |
reactome | R-HSA-5689896 | Ovarian tumor domain proteases |
reactome | R-HSA-5693532 | DNA Double-Strand Break Repair |
reactome | R-HSA-5693565 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks |
reactome | R-HSA-5693606 | DNA Double Strand Break Response |
reactome | R-HSA-597592 | Post-translational protein modification |
reactome | R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling |
reactome | R-HSA-6791312 | TP53 Regulates Transcription of Cell Cycle Genes |
reactome | R-HSA-6796648 | TP53 Regulates Transcription of DNA Repair Genes |
reactome | R-HSA-6803204 | TP53 Regulates Transcription of Genes Involved in Cytochrome C Release |
reactome | R-HSA-6803205 | TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain |
reactome | R-HSA-6803207 | TP53 Regulates Transcription of Caspase Activators and Caspases |
reactome | R-HSA-6803211 | TP53 Regulates Transcription of Death Receptors and Ligands |
reactome | R-HSA-6804114 | TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest |
reactome | R-HSA-6804115 | TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain |
reactome | R-HSA-6804116 | TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest |
reactome | R-HSA-6804754 | Regulation of TP53 Expression |
reactome | R-HSA-6804756 | Regulation of TP53 Activity through Phosphorylation |
reactome | R-HSA-6804757 | Regulation of TP53 Degradation |
reactome | R-HSA-6804758 | Regulation of TP53 Activity through Acetylation |
reactome | R-HSA-6804759 | Regulation of TP53 Activity through Association with Co-factors |
reactome | R-HSA-6804760 | Regulation of TP53 Activity through Methylation |
reactome | R-HSA-6806003 | Regulation of TP53 Expression and Degradation |
reactome | R-HSA-6807070 | PTEN Regulation |
reactome | R-HSA-6807070 | PTEN Regulation |
reactome | R-HSA-6811555 | PI5P Regulates TP53 Acetylation |
reactome | R-HSA-69275 | G2/M Transition |
reactome | R-HSA-69278 | Cell Cycle, Mitotic |
reactome | R-HSA-69473 | G2/M DNA damage checkpoint |
reactome | R-HSA-69481 | G2/M Checkpoints |
reactome | R-HSA-69541 | Stabilization of p53 |
reactome | R-HSA-69560 | Transcriptional activation of p53 responsive genes |
reactome | R-HSA-69563 | p53-Dependent G1 DNA Damage Response |
reactome | R-HSA-69580 | p53-Dependent G1/S DNA damage checkpoint |
reactome | R-HSA-69615 | G1/S DNA Damage Checkpoints |
reactome | R-HSA-69620 | Cell Cycle Checkpoints |
reactome | R-HSA-69895 | Transcriptional activation of cell cycle inhibitor p21 |
reactome | R-HSA-73857 | RNA Polymerase II Transcription |
reactome | R-HSA-73894 | DNA Repair |
reactome | R-HSA-74160 | Gene expression (Transcription) |
reactome | R-HSA-8852276 | The role of GTSE1 in G2/M progression after G2 checkpoint |
reactome | R-HSA-8878159 | Transcriptional regulation by RUNX3 |
reactome | R-HSA-8941855 | RUNX3 regulates CDKN1A transcription |
reactome | R-HSA-8943724 | Regulation of PTEN gene transcription |
reactome | R-HSA-8943724 | Regulation of PTEN gene transcription |
reactome | R-HSA-8953897 | Cellular responses to external stimuli |
reactome | R-HSA-9006925 | Intracellular signaling by second messengers |
reactome | R-HSA-9006925 | Intracellular signaling by second messengers |
reactome | R-HSA-983231 | Factors involved in megakaryocyte development and platelet production |
biocarta | arfpathway | tumor suppressor arf inhibits ribosomal biogenesis |
biocarta | atmpathway | atm signaling pathway |
biocarta | atrbrcapathway | role of brca1 brca2 and atr in cancer susceptibility |
biocarta | btg2pathway | btg family proteins and cell cycle regulation |
biocarta | chemicalpathway | apoptotic signaling in response to dna damage |
biocarta | efppathway | estrogen responsive protein efp controls cell cycle and breast tumors growth |
biocarta | g1pathway | cell cycle: g1/s check point |
biocarta | g2pathway | cell cycle: g2/m checkpoint |
biocarta | p53hypoxiapathway | hypoxia and p53 in the cardiovascular system |
biocarta | p53pathway | p53 signaling pathway |
biocarta | plk3pathway | regulation of cell cycle progression by plk3 |
biocarta | pmlpathway | regulation of transcriptional activity by pml |
biocarta | rbpathway | rb tumor suppressor/checkpoint signaling in response to dna damage |
biocarta | rnapathway | double stranded rna induced gene expression |
biocarta | telpathway | telomeres telomerase cellular aging and immortality |
biocarta | tertpathway | overview of telomerase protein component gene htert transcriptional regulation |
biocarta | tidpathway | chaperones modulate interferon signaling pathway |
Gene-Drug: Aster Plot
Drug ID | Drug Name | Model Num. |
---|---|---|
iGMDRD147 | Prima-1 | 1 |
iGMDRD552 | AZD-1775 | 3 |
iGMDRD264 | Bryostatin 1 | 1 |
iGMDRD322 | FK 866 | 4 |
iGMDRD367 | Ro 28-1675 | 1 |
iGMDRD993 | QL-XII-61 | 1 |
iGMDRD662 | JQ-1 | 2 |
iGMDRD455 | Idelalisib | 1 |
iGMDRD215 | CCT007093 | 1 |
iGMDRD311 | Dacinostat | 1 |
iGMDRD213 | SMR000068650 | 1 |
iGMDRD77 | Itraconazole | 1 |
iGMDRD103 | SN-38 | 3 |
iGMDRD121 | GMX1778 | 2 |
iGMDRD158 | NSC141540 | 6 |
iGMDRD293 | Bleomycin | 3 |
iGMDRD137 | Indisulam | 8 |
iGMDRD5 | Tyrphostin AG 1478 | 2 |
iGMDRD879 | chemotherapy | 2 |
iGMDRD1002 | rTRAIL | 2 |
iGMDRD883 | CIL55A | 1 |
iGMDRD154 | NSC23766 | 2 |
iGMDRD775 | NCGC00346967-01 | 1 |
iGMDRD314 | Tanespimycin | 2 |
iGMDRD352 | PD-0325901 | 1 |
iGMDRD237 | ABT-751 | 2 |
iGMDRD560 | MK-2206 | 1 |
iGMDRD110 | ETOMOXIR | 1 |
iGMDRD50 | Cytarabine | 1 |
iGMDRD276 | AS 605240 | 1 |
iGMDRD79 | Gemcitabine | 10 |
iGMDRD475 | BX 912 | 1 |
iGMDRD719 | IOX2 | 1 |
iGMDRD992 | QL-VIII-58 | 1 |
iGMDRD356 | PNU-74654 | 1 |
iGMDRD23 | Gossypol | 1 |
iGMDRD602 | Foretinib | 1 |
iGMDRD133 | Lapatinib | 1 |
iGMDRD730 | Kahalalide F | 1 |
iGMDRD146 | Elesclomol | 1 |
iGMDRD468 | AZ628 | 1 |
iGMDRD187 | BRD9876 | 1 |
iGMDRD920 | HSP90 inhibitor | 4 |
iGMDRD568 | SCHEMBL15005512 | 1 |
iGMDRD458 | GSK-319347A | 1 |
iGMDRD493 | GSK269962A | 4 |
iGMDRD259 | EX-527 | 1 |
iGMDRD470 | Trametinib | 1 |
iGMDRD778 | SCHEMBL13586708 | 1 |
iGMDRD1032 | VNLG/124 | 1 |
iGMDRD363 | OSI-930 | 1 |
iGMDRD793 | BEC (hydrochloride) | 3 |
iGMDRD21 | Fluorouracil | 2 |
iGMDRD61 | Kinetin riboside | 4 |
iGMDRD748 | PHA-665752 | 2 |
iGMDRD546 | BMS-754807 | 7 |
iGMDRD670 | ML 210 | 4 |
iGMDRD403 | BAY 61-3606 | 3 |
iGMDRD397 | Pazopanib | 1 |
iGMDRD409 | Saracatinib | 1 |
iGMDRD433 | Lexibulin | 1 |
iGMDRD654 | SL 0101-1 | 1 |
iGMDRD749 | ZINC6718453 | 1 |
iGMDRD425 | ERASTIN | 4 |
iGMDRD886 | Compound 1541A | 3 |
iGMDRD179 | Shikonin | 2 |
iGMDRD876 | CDK4/CDK6 inhibitor (abemaciclib) | 1 |
iGMDRD246 | NPC26 | 4 |
iGMDRD695 | FR-180204 | 2 |
iGMDRD384 | EHT-1864 | 1 |
iGMDRD42 | Vorinostat | 1 |
iGMDRD882 | CIL41 | 3 |
iGMDRD650 | Abemaciclib | 1 |
iGMDRD3 | PD-173074 | 2 |
iGMDRD755 | XMD13-2 | 2 |
iGMDRD544 | Vismodegib (GDC-0449) | 1 |
iGMDRD88 | AICA ribonucleotide | 1 |
iGMDRD434 | BMS-536924 | 3 |
iGMDRD192 | CIL56 | 2 |
iGMDRD808 | Alemtuzumab | 1 |
iGMDRD267 | Oligomycin A | 2 |
iGMDRD785 | XMD15-27 | 1 |
iGMDRD1016 | THZ-2-49 | 1 |
iGMDRD310 | Everolimus | 3 |
iGMDRD211 | (1S,3R)-RSL3 | 2 |
iGMDRD177 | Teniposide | 1 |
iGMDRD450 | JNJ-26854165 | 1 |
iGMDRD435 | BI-2536 | 1 |
iGMDRD132 | (-)-gallocatechin-3-O-gallate | 4 |
iGMDRD85 | Ursolic acid | 4 |
iGMDRD536 | PLX-4720 | 1 |
iGMDRD116 | CD437 | 2 |
iGMDRD125 | BIRB-796 | 2 |
iGMDRD160 | Cis-Platin | 5 |
iGMDRD424 | Tamatinib | 1 |
iGMDRD652 | UNC0638 | 1 |
iGMDRD307 | Manumycin A | 2 |
iGMDRD512 | nutlin 3 | 1 |
iGMDRD792 | Cetuximab | 2 |
iGMDRD291 | AC1NS4S0 | 1 |
iGMDRD454 | JNK Inhibitor VIII | 1 |
iGMDRD453 | GW2580 | 2 |
iGMDRD887 | Compound 23 citrate | 3 |
iGMDRD432 | AT-7519 | 2 |
iGMDRD440 | Nutlin-3A | 21 |
iGMDRD309 | 17AAG | 1 |
iGMDRD390 | MDM2 inhibitor | 2 |
iGMDRD320 | PIK-93 | 2 |
iGMDRD33 | Entinostat | 1 |
iGMDRD134 | Sorafenib | 2 |
iGMDRD378 | ZM-447439 | 1 |
iGMDRD280 | CYTOCHALASIN B | 1 |
iGMDRD375 | GW-405833 | 2 |
iGMDRD218 | XAV 939 | 1 |
iGMDRD776 | QL-XI-92 | 2 |
iGMDRD446 | LY 2183240 | 1 |
iGMDRD281 | Vinorelbine base | 1 |
iGMDRD253 | Vincaleukoblastine | 1 |
iGMDRD498 | GW441756X | 1 |
iGMDRD718 | Pyrvinium pamoate | 4 |
iGMDRD66 | Doxorubicin | 7 |
iGMDRD144 | NSC95397 | 2 |
iGMDRD494 | Neopeltolide | 1 |
iGMDRD129 | SB-216763 | 1 |
iGMDRD361 | 5Z-7-Oxozeaenol | 1 |
iGMDRD599 | Salermide | 6 |
iGMDRD579 | PF750 | 1 |
iGMDRD286 | Nsc 632839 | 1 |
iGMDRD366 | PI-103 | 4 |
iGMDRD705 | Nakiterpiosin | 1 |
iGMDRD660 | GSK-1070916 | 2 |
iGMDRD289 | Parthenolide | 2 |
iGMDRD105 | Triptolide | 1 |
iGMDRD288 | Carboplatin | 1 |
iGMDRD667 | BIX02189 | 1 |
iGMDRD496 | Pramlintide [USAN] | 3 |
iGMDRD402 | AKT Inhibitor VIII | 2 |
iGMDRD467 | Motesanib | 1 |
iGMDRD722 | AZD6738 | 4 |
iGMDRD176 | Decitabine | 4 |
iGMDRD49 | Mitomycin | 7 |
iGMDRD341 | Triacsin c | 4 |
iGMDRD541 | SNX-2112 (PF-04928473) | 1 |
iGMDRD150 | RITA | 4 |
iGMDRD532 | Olaparib | 3 |
iGMDRD594 | AZD-8055 | 1 |
iGMDRD523 | Cyanoquinoline, 11 | 1 |
iGMDRD564 | GSK-650394 | 1 |
iGMDRD48 | Dexamethasone | 2 |
iGMDRD248 | BRD4354 | 1 |
iGMDRD190 | Nilotinib | 1 |
iGMDRD524 | ISX-9 | 3 |
iGMDRD188 | Piperlongumine | 2 |
iGMDRD399 | Selumetinib | 4 |
iGMDRD391 | OSU-03012 | 1 |
iGMDRD284 | Palbociclib | 1 |
iGMDRD429 | Amuvatinib | 2 |
iGMDRD117 | Docetaxel | 2 |
iGMDRD1019 | TL-2-105 | 1 |
iGMDRD801 | 2,4-dideoxy-DC-45-A2 | 2 |
iGMDRD44 | Temozolomide | 1 |
iGMDRD593 | CX-5461 | 1 |
iGMDRD52 | Rotenone | 2 |
iGMDRD474 | Avrainvillamide | 2 |
iGMDRD394 | BX-795 | 1 |
iGMDRD687 | I-BET151 | 1 |
iGMDRD107 | Valdecoxib | 1 |
iGMDRD316 | N9-Isopropyl-olomoucine | 1 |
iGMDRD2 | PK-11195 | 2 |
iGMDRD152 | 179324-69-7 | 1 |
iGMDRD1033 | WEE1 inhibitor | 3 |
iGMDRD283 | Bosutinib | 1 |
iGMDRD135 | Lenalidomide | 1 |
iGMDRD781 | Sirolimus | 2 |
iGMDRD126 | Tipifarnib | 2 |
iGMDRD151 | CHM-1 | 2 |
iGMDRD571 | Cabozantinib | 1 |
iGMDRD443 | Linifanib | 1 |
iGMDRD420 | Leucascandrolide A | 2 |
iGMDRD937 | KIN001-236 | 1 |
iGMDRD300 | Tozasertib | 3 |
iGMDRD505 | Pevonedistat | 1 |
iGMDRD935 | JQ12 | 1 |
iGMDRD646 | PHA-793887 | 2 |
iGMDRD172 | T091317 | 1 |
iGMDRD389 | SB525334 | 1 |
iGMDRD459 | RO-3306 | 2 |
iGMDRD504 | Obatoclax | 1 |
iGMDRD68 | Paclitaxel | 2 |
iGMDRD374 | Zibotentan (ZD4054) | 1 |
iGMDRD292 | NSC87877 | 1 |
iGMDRD368 | Oxaliplatin | 1 |
iGMDRD456 | Crizotinib | 2 |
iGMDRD614 | Dabrafenib | 2 |
iGMDRD345 | Compound 10b [PMID: 11504634] | 3 |
iGMDRD701 | NVP-AUY922 | 1 |
iGMDRD497 | 16beta-Bromoandrosterone | 1 |
iGMDRD382 | CEP-701 | 2 |
iGMDRD262 | KU-55933 | 1 |
iGMDRD360 | SB-505124 | 1 |
iGMDRD347 | Y-39983 | 6 |
iGMDRD690 | PRIMA-1MET | 1 |
iGMDRD131 | Erlotinib | 1 |
iGMDRD332 | A-770041 | 1 |
iGMDRD577 | BIX01294 | 5 |
iGMDRD398 | Sepantronium | 1 |
iGMDRD562 | Navitoclax | 2 |
iGMDRD573 | GSK-1904529A | 2 |
iGMDRD758 | JW-7-24-1 | 1 |
iGMDRD782 | DC-45-A2 | 4 |
iGMDRD388 | YM201636 | 1 |
iGMDRD759 | PFI-1 | 3 |
iGMDRD478 | ABT-888 | 1 |
iGMDRD870 | BRD63610 | 1 |
iGMDRD574 | Ruxolitinib | 1 |
iGMDRD669 | PDK1 inhibitor | 2 |
iGMDRD509 | NVP-BHG712 | 2 |
iGMDRD491 | TAE-684 | 1 |
iGMDRD255 | SB225002 | 2 |
iGMDRD109 | Gefitinib | 1 |
iGMDRD401 | Afatinib | 1 |
iGMDRD673 | LSM-1215 | 1 |
iGMDRD83 | Capecitabine | 1 |
iGMDRD805 | Adjuvant Chemotherapy | 2 |
iGMDRD189 | CGP 60474 | 1 |
iGMDRD608 | Refametinib | 1 |
iGMDRD163 | all trans Retinoic Acid | 1 |
iGMDRD112 | Methotrexate | 1 |
iGMDRD136 | Nutlin-3 | 1 |
iGMDRD387 | CHIR-99021 | 3 |
iGMDRD1008 | SR-II-138A | 4 |
iGMDRD659 | Avagacestat (BMS-708163) | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in TP53